Loomis, Sayles & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $159M | Sell |
487,328
-10,156
| -2% | -$3.31M | 0.2% | 57 |
|
|
2025
Q1 | $134M | Sell |
497,484
-5,561
| -1% | -$1.5M | 0.19% | 58 |
|
|
2024
Q4 | $118M | Sell |
503,045
-22,258
| -4% | -$5.24M | 0.15% | 62 |
|
|
2024
Q3 | $144M | Sell |
525,303
-43,979
| -8% | -$12.1M | 0.19% | 61 |
|
|
2024
Q2 | $138M | Sell |
569,282
-12,569
| -2% | -$3.05M | 0.19% | 60 |
|
|
2024
Q1 | $87M | Sell |
581,851
-26,877
| -4% | -$4.02M | 0.12% | 71 |
|
|
2023
Q4 | $117M | Sell |
608,728
-16,673
| -3% | -$3.19M | 0.18% | 64 |
|
|
2023
Q3 | $111M | Sell |
625,401
-19,742
| -3% | -$3.5M | 0.19% | 62 |
|
|
2023
Q2 | $123M | Sell |
645,143
-13,083
| -2% | -$2.48M | 0.2% | 60 |
|
|
2023
Q1 | $132M | Sell |
658,226
-54,330
| -8% | -$10.9M | 0.23% | 57 |
|
|
2022
Q4 | $169M | Sell |
712,556
-35,194
| -5% | -$8.36M | 0.34% | 53 |
|
|
2022
Q3 | $150M | Sell |
747,750
-80,329
| -10% | -$16.1M | 0.3% | 52 |
|
|
2022
Q2 | $121M | Sell |
828,079
-40,669
| -5% | -$5.93M | 0.22% | 57 |
|
|
2022
Q1 | $142M | Sell |
868,748
-127,689
| -13% | -$20.9M | 0.19% | 57 |
|
|
2021
Q4 | $169M | Buy |
996,437
+28,330
| +3% | +$4.8M | 0.2% | 56 |
|
|
2021
Q3 | $183M | Buy |
968,107
+22,042
| +2% | +$4.16M | 0.22% | 57 |
|
|
2021
Q2 | $160M | Buy |
+946,065
| New | +$160M | 0.19% | 61 |
|